Author Archives: Patricia Inacio PhD

COPD Foundation, DevPro Biopharma Partner to Boost New Therapy Development

The Chronic Obstructive Pulmonary Disease Foundation and DevPro Biopharma have established a partnership to develop new therapies for people with chronic obstructive pulmonary disease (COPD) and other lung disorders. The collaborators will work to identify potential therapies and speed their development and possible regulatory approval. The aim is to enable new treatments…

Partnership Brings Quantitative Imaging Analysis to Diagnosis, Care

A new collaboration is seeking to bring quantitative imaging analysis to diagnosis and care of patients with chronic lung diseases, including chronic obstructive pulmonary disease (COPD) and emphysema. The agreement is between Spesana, a healthcare platform focused on molecular diagnostics and in building an accessible database for physicians,…

Trixeo Aerosphere Approved in EU for COPD

The European Commission has approved AstraZeneca‘s triple combination therapy Trixeo Aerosphere as a maintenance treatment for chronic obstructive pulmonary disease (COPD). The approval, which follows a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), covers the therapy’s use in adults with moderate-to-severe COPD…

Vaping Linked to Higher Respiratory Disease Risk in Large US Study

Use of electronic cigarettes (e-cigarettes) is associated with an increased risk of respiratory diseases, including chronic obstructive pulmonary disease (COPD), among young adults, irrespective of other tobacco product use, a large U.S.-based study shows. Compared to healthy people, those currently using e-cigarettes, commonly called vaping, had a 43% increased…